Key facts
- Rimidi’s last known valuation is $32.0M (Jul 2018).
- It has raised $22.6M across 8 recorded rounds; the latest was Seed Round ($450K) in Aug 2025.
- Notable investors include Impact Assets, Springboard Enterprises, Village Capital, VentureWell, Album VC — 22 tracked in total.
- Rimidi has filed 7 Form Ds with the SEC since 2018, most recently Aug 2025 ($450K sold to 1 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Rimidi
Funding rounds
8 roundsAbout Rimidi
Developer of cloud-based software designed to enable chronic disease management. The company's platform works within the EHR and combines patient-generated health data from connected devices with clinical data to drive patient-specific insights and provides a risk stratification view, enabling clinicians to remotely monitor their patient's progress and virtually send encouragement or treatment adjustments when necessary.
- Industry
- Enterprise Systems (Healthcare)
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2012
- Employees
- 32
- Website
- rimidi.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Rimidi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rimidi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rimidi in its N-PORT filings yet. We sweep new filings monthly.